Arbutus Biopharma Corporation
General ticker "ABUS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $682.9M (TTM average)
Arbutus Biopharma Corporation follows the US Stock Market performance with the rate: 56.4%.
Estimated limits based on current volatility of 2.9%: low 4.44$, high 4.70$
Factors to consider:
- Total employees count: 73 (-27.0%) as of 2023
- Top business risk factors: Inability to raise capital, Third-party risks, Early stage company risks, Operational and conduct risks, Labor/talent shortage/retention
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.47$, 6.70$]
- 2026-12-31 to 2027-12-31 estimated range: [3.50$, 6.73$]
Financial Metrics affecting the ABUS estimates:
- Positive: with PPE of -27.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.43 <= 0.07
- Positive: Investing cash flow per share per price, % of 1.74 > -0.65
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 80.93 > 64.25
- Positive: Interest expense per share per price, % of 0.01 <= 0.73
Short-term ABUS quotes
Long-term ABUS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $18.14MM | $6.17MM | $14.08MM |
| Operating Expenses | $96.24MM | $82.49MM | $41.13MM |
| Operating Income | $-78.10MM | $-76.32MM | $-27.05MM |
| Non-Operating Income | $5.25MM | $6.40MM | $-6.45MM |
| Interest Expense | $0.46MM | $0.14MM | $0.10MM |
| R&D Expense | $73.70MM | $54.04MM | $25.24MM |
| Income(Loss) | $-72.85MM | $-69.92MM | $-33.50MM |
| Profit(Loss)* | $-72.85MM | $-69.92MM | $-33.50MM |
| Stockholders Equity | $106.02MM | $97.37MM | $76.58MM |
| Assets | $144.40MM | $131.71MM | $94.62MM |
| Operating Cash Flow | $-85.94MM | $-64.85MM | $-39.64MM |
| Capital expenditure | $1.01MM | $0.18MM | $0.00MM |
| Investing Cash Flow | $50.77MM | $22.95MM | $15.58MM |
| Financing Cash Flow | $30.65MM | $52.00MM | $5.72MM |
| Earnings Per Share** | $-0.44 | $-0.38 | $-0.17 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.